Product Information
INTUNIV ER 1 MG TABLET is a brand product labeled by Takeda Pharmaceuticals America, Inc., priced at $9.3865 per EA under NDC 54092051302. Its NADAC has been published 306 times since Nov 28, 2013.
FDA first approved this application on Sep 2, 2009. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
The High Outlier badge above means this manufacturer's average price in the guanfacine market falls above Q3 + 1.5·IQR across all competing manufacturers. We only apply this flag in markets with four or more competitors. Full definition: glossary → outlier.
Strength
1 mg/1
Manufacturer
Takeda Pharmaceuticals America, Inc.NDC
54092051302
Classification
Brand
Dosage Form
TABLET, EXTENDED RELEASE
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
GUANFACINE HYDROCHLORIDEApproval Type
New Drug (NDA)
FDA Application
NDA022037FDA Approved
9/2/2009
TE Code
AB
On Market Since
9/2/2009
Pharmacological Classes
Price Statistics
The NADAC for INTUNIV ER 1 MG TABLET has been published 306 times since Nov 28, 2013, and over the history we have for it it has risen 20.9%. The table below summarizes its recorded NADAC range and movement.
| Current price | $9.3865 per EA |
|---|---|
| All-time high | $9.4216 (Mar 16, 2016) |
| All-time low | $7.7607 (Nov 28, 2013) |
| 52-week high | $9.3973 |
| 52-week low | $9.2988 |
| Median price | $9.3421 |
| Average price | $9.2223 |
| Largest weekly change | +12.0% (Jul 9, 2014) |
| Weeks tracked | 306 |
| Tracking since | Nov 28, 2013 |
Generic Alternatives
The matcher finds 5 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 99% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Takeda Pharmaceuticals America, Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
guanfacine market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Central alpha-2 Adrenergic Agonist class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of INTUNIV ER 1 MG TABLET?
The current National Average Drug Acquisition Cost (NADAC) for INTUNIV ER 1 MG TABLET, manufactured by Takeda Pharmaceuticals America, Inc., is $9.3865 per EA (NDC 54092051302), effective Sep 30, 2026.
How has the price of INTUNIV ER 1 MG TABLET changed over time?
Over the history we have for it, the NADAC for INTUNIV ER 1 MG TABLET has risen 20.9%. It has been tracked across 306 weekly CMS publications since Nov 28, 2013.
What are the highest and lowest recorded NADAC prices for INTUNIV ER 1 MG TABLET?
Since Nov 28, 2013, the NADAC for INTUNIV ER 1 MG TABLET has ranged from a low of $7.7607 (Nov 28, 2013) to a high of $9.4216 (Mar 16, 2016), with a median of $9.3421 per EA.
Are there cheaper alternatives to INTUNIV ER 1 MG TABLET?
Yes. 5 manufacturers publish a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, GUANFACINE HCL ER 1 MG TABLET, is $0.1326 per EA — about 99% below INTUNIV ER 1 MG TABLET.
Who manufactures INTUNIV ER 1 MG TABLET?
INTUNIV ER 1 MG TABLET (NDC 54092051302) is labeled by Takeda Pharmaceuticals America, Inc., and CMS classifies it as a brand product.